Critical Path Should Follow GMP Model, FDA’s Woodcock Says
This article was originally published in The Pink Sheet Daily
Executive Summary
To avoid public pushback, the Critical Path initiative should focus on science, not regulatory overhauls, Woodcock tells DIA.